Acadian Asset Management
TOVX icon

Acadian Asset Management’s Theriva Biologics TOVX Stock Holding History

Acadian Asset Management’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-291
Closed -$28K – 2318
2020
Q4 		$28K Hold
291
– – ﹤0.01% 2084
2020
Q3 		$35K Buy
291
+47
+19% +$6.27K ﹤0.01% 1947
2020
Q2 		$31K Buy
+244
New +$23.3K ﹤0.01% 2034

Other funds holding TOVX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $76.8M AUM 34.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Acadian Asset Management's TOVX Position: Q1 2021 in Review

Acadian Asset Management sold out of Theriva Biologics (TOVX) in Q1 2021, closing a stake of 291 shares — an estimated $28K sold.

Acadian Asset Management first reported a position in TOVX in Q2 2020 and held it in 3 quarters. The position peaked at $35K in Q3 2020. 27 funds tracked by Wall St. Rank hold TOVX as of Q1 2021.

  • Acadian Asset Management reported no remaining Theriva Biologics position as of Q1 2021 after selling out during the quarter.
  • Acadian Asset Management sold 291 Theriva Biologics shares in Q1 2021, an estimated $28K.
  • Acadian Asset Management first reported a position in Theriva Biologics in Q2 2020 and held it in 3 quarters.
  • Acadian Asset Management's Theriva Biologics position peaked at $35K in Q3 2020.
  • 27 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2021.

Based on Acadian Asset Management's 13F filing for Q1 2021, filed 11 May 2021.